Summary: Allergic rhinitis is one of the most common allergic diseases in Poland. It is an inflammatory disease and its main symptoms are runny nose, sneezing, itchy nose, blocked nose or nasal congestion, and eye symptoms such as itching, tearing, burning or redness of the cornea. AR is a disease burdensome for the patient, it causes sleep disturbances, fatigue, cognitive disorders, irritability, and thus lower efficiency at school and work, and a significant reduction in the quality of life of patients and, consequently, high indirect costs related to absenteeism from work and school. In order to optimize treatment and achieve the best therapeutic effect, the extremely important role of integrated care for patients (ICPs), which is patient-centered and personalized, is currently underlined. Therefore, the current treatment recommendations take into account not only randomized clinical trials, but also data from real-world evidence (RWE) and studies in allergen chambers. Real-life clinical practice in the treatment of allergic rhinitis and real-life studies show that the combination of azelastine with intranasal glucocorticosteroid (MP-AzeFlu) is more effective than just INCS. MP-AzeFlu alleviates the symptoms of AR and improves patients' quality of life through better sleep quality and less disruption to work, school, social life and outdoor activities. Currently we also have a second combined preparation containing mometasone furoate and olopatadine the effectiveness of which has been demonstrated in clinical trials.